The U.S. market for long-acting local anesthetics is highly concentrated, with a pre-acquisition HHI of 6,682. Astra is the leading supplier of long-acting local anesthetics in the United States and worldwide, and is one of only two companies (along with Abbott Laboratories) with Food and Drug Administration (''FDA'') approval for the manufacture and sale of long-acting local anesthetics in the United States. While Zeneca does not currently sell long-acting local anesthetics, it had entered into an agreement with Chiroscience to market and assist in the development of levobupivacaine (known commercially as Chirocaine), a new long-acting local anesthetic being developed by Chiroscience. Thus, through this agreement with Chiroscience, Zeneca is an actual potential competitor in the U.S. market for long-acting local anesthetics.

The impending introduction of levobupivacaine in 1999 was expected to result in increased competition in the U.S. market for long-acting local anesthetics, leading to lower prices and potential improvements in product safety. The proposed merger of Zeneca and Astra would eliminate this significant source of new competition and leave the long-acting local anesthetic market highly concentrated for the foreseeable future.

It is unlikely that this lost competition would have been replaced by new competitors due to the substantial barriers to entry that exist in the U.S. market for long-acting local anesthetics. A new entrant into this market would need to undertake the difficult, expensive and time-consuming process of researching and developing a new product, obtaining FDA approval and gaining customer acceptance. Because of the difficulty of accomplishing these tasks, new entry into this market, other than Zeneca's and Chiroscience's imminent introduction of levobupivacaine, would not be timely, likely or sufficient to deter or counteract the anticompetitive effects resulting from the merger.

The proposed Consent Order effectively remedies the merger's anticompetitive effects in the U.S. market for long-acting local anesthetics by requiring Zeneca to transfer and surrender all of its rights and assets relating to levobupivacaine to Chiroscience, the developer of levobupivacaine, no later than ten (10) business days after the date the Commission accepts the Consent Agreement for public comment. Under the terms of the Consent Order, Zeneca is required to transfer and surrender these assets pursuant to an agreement entered into between Chiroscience and Zeneca that is defined in the Agreement Containing Consent Order as the ''Chiroscience/Zeneca Agreement.'' The assets to be transferred to Chiroscience consist principally of intellectual property and know-how and include, among other things, all of the applicable patents, trademarks, copyrights, technical information and market research relating to lovobupivacaine. In addition, the Consent Order requires Zeneca to comply with the other provisions of the Chiroscience/Zeneca Agreement. That agreement establishes, among other things, a trasitional period during which Zeneca is required to continue carrying our certain ongoing activities relating to the commercialization of levobupivacaine, including manufacturing, regulatory, clinical, development and marketing activities. The Chiroscience/Zeneca Agreement also contains provisions that will protect the confidentiality of any informaiton provided by Chiroscience to Zeneca in the past, or during the transitional period.

In addition, the Consent Order requires Zeneca to divest its approximately 3% investment interest in Chiroscience within four (4) months of the expiration of the Agreement Amending Share Subscription Agreement, as defined in the proposed Consent Order. Pending divestiture of this investment interest, the Order prohibits Zeneca from, directly or indirectly: (i) Exercising dominion or control over, or otherwise seeking to influence, the management, direction or supervision of the business of Chiroscience; (ii) seeking or obtaining representation on the Board of Directors of Chiroscience; (iii) exercising any voting rights attached to the investment interest; (iv) seeking or obtaining access to any confidential or proprietary informaiton of Chiroscience; or (v) taking any action or failing to take any action in a manner that would be incompatible with the status of Zeneca as a passive investor in Chiroscience.

The proposed Consent Order also requires Zeneca to provide the Commission a report of compliance with the Order within thirty (30) days following the date the Order becomes final and every ninety (90) days thereafter until its has complied with the terms of the Order. Finally, the Order allows the Commission to appoint an Interim Trustee to facilitate an orderly transfer of the levobupivacaine assets and to ensure that Zeneca carries out its obligations under the Consent Agreement and the Chiroscience/Zeneca Agreement.

The purpose of this analysis is to facilitate public comment on the proposed Order, and it is not intended to constitute an official interpretation of the agreement and proposed Order or to modify in any way their terms.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 99–7752 Filed 3–29–99; 8:45 am]

BILLING CODE 6750–01–M

GENERAL SERVICES ADMINISTRATION

Federal Supply Service; Revisions to the General Services Administration's (GSA's) Centralized Household Goods Traffic Management Program (CHAMP)

AGENCY: Federal Supply Service, GSA.

ACTION: Notice of proposed program changes for comment.

SUMMARY: This notice invites comments on GSA's revised plan to increase the CHAMP shipment surcharge from $45 to $145 instead of $105 as proposed in our January 20, 1999, **Federal Register** notice published for comment (64 FR 3131). Further evaluation of the program's funding status has clearly demonstrated that this action is necessary to increase CHAMP funding to a level that will enable GSA to defray the program's expenses. This notice supersedes the January 20, 1999 **Federal Register** notice.

DATES: Please submit your comments by April 29, 1999.

ADDRESSES: Mail comments to the Transportation Management Division (FBF), General Services Administration, Washington, DC 20406, Attn: **Federal Register** Surcharge Increase Notice. GSA will consider your comments prior to implementing the proposed increase.

FOR FURTHER INFORMATION CONTACT: Larry Tucker, Senior Program Expert, Transportation Management Division, FSS/GSA, 703–305–5745.

SUPPLEMENTARY INFORMATION: GSA's CHAMP receives no Congressional funding and must depend on a shipment surcharge, currently $45, to defray its costs. The shipment surcharge has been in effect since 1996 and no longer fully funds program expenses. GSA published a notice for comment in the **Federal Register** on January 20, 1999 (64 FR 3131) announcing its plan to increase the shipment surcharge from $45 to $105, and to revise the Household Goods Tender of Service ''shipment definition'' for the purpose of assessing the surcharge on each component of a shipment (i.e.,

households, privately owned vehicle (POV), and unaccompanied baggage) to allow us to recoup program costs.

Agency/industry comments GSA received on the proposed changes and our own programmatic concerns suggest it is time for GSA to change the way CHAMP industrial funding fees are collected. We plan to work with our Federal agency and industry partners to develop and implement an alternative funding strategy by November 1, 1999. In the interim it is necessary for us to increase the shipment surcharge. Our ongoing analysis of the program's financial status clearly indicates that $105 would not adequately cover program expenses even with cost cutting measures we have identified and are proceeding to implement. Indeed, our in-depth analysis indicates we must increase the surcharge to $145 to adequately cover our expenses of maintaining this valuable program.

We do, however, withdraw the January 20th proposal to add the surcharge to POV and unaccompanied baggage shipments. Moreover, instead of a line-haul transportation rate increase to cover the $145 surcharge, GBL issuers are to include the surcharge as a separate line item on the GBL. Carriers then will bill Federal agencies for the surcharge as a separate line item on the SF–1113.

GSA is committed to providing a program that meets the needs of Federal agencies. The funding increase will be used to pay for personnel who directly support the program and activities associated with the development of program enhancements. Moreover, we are looking forward to working with our customer agency counterparts and industry partners to devise by November 1, 1999, a satisfactory approach to handling future funding for this important program.

Dated: March 25, 1999.

Barbara Vogt,

Deputy Assistant Commissioner, Office of Transportation and Property Management.

[FR Doc. 99–7826 Filed 3–29–99; 8:45 am]

BILLING CODE 6820–24–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Program Announcement 99059]

Childhood Asthma and Hazardous Substances Applied Research and Development Amendment

A notice announcing the availability of fiscal year 1999 funds for the Childhood Asthma and Hazardous Substances Applied Research and Development Program was published in the **Federal Register** on March 19, 1999, (Vol. 64 FR No. 53). The notice is amended as follows:

On page 13585, third column, after item G.4.d. add:

e. The extent to which the applicant has met the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes:

i. The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation.

ii. The proposed justification when representation is limited or absent.

iii. A statement as to whether the design of the study is adequate to measure differences when warranted.

iv. A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community (ies) and recognition of mutual benefits.

Under item G.6. change 9 per cent to 10 percent; delete item G.7. Minority Populations; and change the number for item 8. to 7.

Dated: March 24, 1999.

Georgi Jones,

Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 99–7706 Filed 3–29–99; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[ATSDR–145]

Public Health Assessments Completed

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: This notice announces those sites for which ATSDR has completed public health assessments during the period October 1998 through December 1998. This list includes sites that are on or proposed for inclusion on the National Priorities List (NPL), and includes sites for which assessments were prepared in response to requests from the public.

FOR FURTHER INFORMATION CONTACT: Robert C. Williams, P.E., DEE, Director, Division of Health Assessment and Consultation, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road, NE., Mailstop E–32, Atlanta, Georgia 30333, telephone (404) 639–0610.

SUPPLEMENTARY INFORMATION: The most recent list of completed public health assessments was published in the **Federal Register** on January 28, 1999, (64 FR 4422). This announcement is the responsibility of ATSDR under the regulation, Public Health Assessments and Health Effects Studies of Hazardous Substances Releases and Facilities (42 CFR Part 90). This rule sets forth ATSDR's procedures for the conduct of public health assessments under section 104(i) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), as amended by the Superfund Amendments and Reauthorization Act (SARA) (42 U.S.C. 9604(i)).

Availability

The completed public health assessments and addenda are available for public inspection at the Division of Health Assessment and Consultation, Agency for Toxic Substances and Disease Registry, Building 33, Executive Park Drive, Atlanta, Georgia (not a mailing address), between 8 a.m. and 4:30 p.m., Monday through Friday except legal holidays. The completed public health assessments are also available by mail through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, or by telephone at (703) 605–6000. NTIS charges for copies of public health assessments and addenda. The NTIS order numbers are listed in parentheses following the site names.

Public Health Assesssments Completed or Issued

Between October 1, 1998, and December 31, 1999, public health assessments were issued for the sites listed below: